Cardiovascular risk assessment in diabetes mellitus: Comparison of the general framingham risk profile versus the World Health Organization/ International Society of Hypertension risk prediction charts in Arabs - Clinical implications

Angiology

Volumn 64, Issue 5, 2013, Pages 336-342

  Al Lawati, Jawad A ^a   Barakat, Mohammed N ^a   Al Lawati, Najla A ^a   Al Maskari, Masoud Y ^b   Elsayed, Medhat K ^a   Mikhailidis, Dimitri P ^c   Al Zakwani, Ibrahim S ^b,d  

^a MINISTRY OF HEALTH   (Oman)

^b SULTAN QABOOS UNIVERSITY   (Oman)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Gulf Health Research   (Oman)

Author keywords

cardiovascular disease; diabetes mellitus; general Framingham risk profile; Oman; World Health Organization International Society of Hypertension risk prediction chart

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ANGINA PECTORIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; DRUG COST; FEMALE; FRAMINGHAM RISK SCORE; HEART FAILURE; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; REVIEW; RISK ASSESSMENT; TRANSIENT ISCHEMIC ATTACK;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; GENERAL FRAMINGHAM RISK PROFILE; OMAN; WORLD HEALTH ORGANIZATION/INTERNATIONAL SOCIETY OF HYPERTENSION RISK PREDICTION CHART;

ADULT; AGED; ARABS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG COSTS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OMAN; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; RISK FACTORS;

EID: 84878354683     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712458349     Document Type: Review

References (28)

1. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol. 2010 ; 55 (25). 2878-2886
2. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention ; 2007 :
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 ; 333 (20). 1301-1307
4. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 ; 360 (9326). 7-22
5. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001 ; 357 (9250). 89-95
6. Standards of Medical Care in Diabetes-2012. Diabetes Care. 2012 ; 35 (suppl 1). S11 - S63
7. World Health Organization. WHO/ISH cardiovascular risk prediction charts. http://www.ish-world.com/Documents/colour-charts-24-Aug-07.pdf. Accessed January 19, 2012.
8. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 ; 117 (6). 743-753
9. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 ; 97 (18). 1837-1847
10. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001 ; 101 (6). 671-679
11. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991 ; 22 (3). 312-318
12. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997 ; 96 (1). 44-49
13. Ndindjock R, Gedeon J, Mendis S, Paccaud F, Bovet P. Potential impact of single-risk-factor versus total risk management for the prevention of cardiovascular events in Seychelles. Bull World Health Organ. 2011 ; 89 (4). 286-295
14. Directorate General of Planning. Annual Health Report. 2009. http://www.moh.gov.om/. Accessed December 5, 2010.
15. Kanjilal S, Rao VS, Mukherjee M, et al. Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian Indians. Vasc Health Risk Management. 2008 ; 4 (1). 199-211
16. Yeo WW, Yeo KR. Predicting CHD risk in patients with diabetes mellitus. Diabet Med. 2001 ; 18 (5). 341-344
17. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care. 2007 ; 30 (5). 1292-1293
18. Masding M, Martch F, Cove D. Cardiovascular disease risk reduction in patients with diabetes - is clinical practice effective?. Pract Diab Int. 2000 ; 17 (5). 155
19. Game FL, Bartlett WA, Bayly GR, Jones AF. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. Diabetes Obesity Metab. 2001 ; 3 (4). 279-286
20. Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med. 2004 ; 21 (3). 238-245
21. Al-Rasadi K, Sulaiman K, Panduranga P, Al-Zakwani I. Prevalence, characteristics, and in-hospital outcomes of metabolic syndrome among acute coronary syndrome patients in Oman. Angiology. 2011 ; 62 (5). 381-389
22. Al-Zakwani I, Sulaiman K, Al-Rasadi K, Mikhailidis DP. Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. Curr Med Res Opin. 2011 ; 27 (4). 879-895
23. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991 ; 121 (1 Pt 2). 293-298
24. D'Agostino RB, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001 ; 286 (2). 180-187
25. Liu J, Hong Y, D'Agostino RB, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA. 2004 ; 291 (21). 2591-2599
26. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 ; 339 (4). 229-234
27. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005 ; 28 (12). 2901-2907
28. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009 ; 26 (2). 142-148